Cardiome Pharma Corp, a specialty pharmaceutical company dedicated to the development and commercialization of cardiovascular therapies, has entered into a distribution agreement with Dublin-based UDG Healthcare plc, to fulfill orders and distribute Brinavess (vernakalant intravenous) in Ireland. The initial term of the agreement is for three years effective as of April 1, 2014. Financial details have not been disclosed.
“We are pleased to have entered into this agreement with UDG Healthcare that will maintain Brinavess availability to our customers in Ireland,” said Karim Lalji, Cardiome’s chief commercial officer. “This agreement continues the previously established Brinavess distribution partnership, thereby minimising distribution interruptions to our customers.”
“We are pleased to continue the fulfillment of orders of Brinavess on behalf of Cardiome for the Irish market,” said David Keyes, Director of the Distribution and Hospitals division at UDG Healthcare. “Brinavess is an important therapeutic option for the management of atrial fibrillation and we are excited to continue making it available to our customers.”
UDG Healthcare plc is a leading international provider of services to healthcare manufacturers and pharmacies, with operations in 22 countries including the US, UK, Ireland and Germany.